The Marked Chart Wire · Health
Moderna
Moderna melanoma vaccine cuts recurrence risk by 42 percent
Moderna's personalized cancer vaccine, used with Merck's Keytruda, reduced the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial.
Part of a series: Moderna stock falls on leak, then raises 2026 outlook
